Second, we investigated the cell-permeable NBD peptide as therapeutic option able to inhibit proinflammatory NF-κB activity and improve diabetic kidney disease in the preclinical T2D model. This evidence concerns the gene NFKB1 and type 2 diabetes mellitus.